Classic heparin-induced thrombocytopenia

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

5 events
Sep 2025CPET-based HIIT for MAFLD

Tang Yida — NA

TrialNOT YET RECRUITING
Apr 2025Effects of HIIT and Concurrent HITT/Plyometric Training on Muscle-tendon Structure, Function and Metabolism in Pediatric Population With Obesity at Different Biological Maturation States (HIIT-PRO Kids).

Universidad Nacional Andres Bello — NA

TrialRECRUITING
Nov 2023Avatrombopag vs. Placebo for CIT in GI Malignancies

Hanny Al-Samkari, MD — PHASE2

TrialACTIVE NOT RECRUITING
Aug 2021HITT for the Identification of Mild Traumatic Brain Injury

Rebiscan, Inc.

TrialACTIVE NOT RECRUITING
Mar 1998

Refluden: FDA approved

For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Refluden

Hoechst Marion Roussel

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Refluden

(Lepirudin)Orphan drug

Hoechst Marion Roussel

Approved Mar 1998

View full treatment details on disease page →

Clinical Trial Landscape

2 active trials
1N/A
1Unknown
2Total recruiting
Search clinical trials for Classic heparin-induced thrombocytopenia

Recent News & Research

No recent news articles indexed yet for Classic heparin-induced thrombocytopenia.
Search PubMed for Classic heparin-induced thrombocytopenia

Browse all Classic heparin-induced thrombocytopenia news →

Specialist Network

Top 2 by expertise

View all Classic heparin-induced thrombocytopenia specialists →

Quick Actions